FK973

FK973 is a **novel substituted dihydrobenzoxazine**, chemically a triacetylated derivative of a natural-product antibiotic isolated from *Streptomyces sandaensis*. Structurally related to mitomycin C, it exhibits potent **antitumor activity** in vitro and in vivo against multiple solid and hematologic tumor models, including lung, colon, melanoma, breast, and oral cancers. FK973 is a cytotoxic agent that exerts its antineoplastic effect by metabolic activation in the cytoplasm to form **DNA interstrand cross-links and DNA-protein cross-links**, leading to inhibition of DNA synthesis and cell death[1][3][4][7][9]. Unlike mitomycin, FK973 shows activity against several drug-resistant tumor cell lines and has a broader effective dose range. Phase I clinical studies indicate the main dose-limiting toxicity is a delayed vascular leak syndrome, though reversible myelosuppression and other toxicities have been observed.

Other names

11-acetyl-8-carbamoyloxymethyl-4-formyl-14-oxa-1,11-diazatetracyclo[7.4.1.02,7.010,12]tetradeca-2,4,6-trien-6,9-diyl diacetate114580-45-9UNII-0X1IR6U63GUNII0X1IR6U63GUNII 0X1IR6U63G